---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-033612"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-07-01T23:59:59+00:00"
generated_at: "2026-05-18T09:56:38.356389+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints Craig Thompson to Board of Directors; board now has eight members

## Summary
- Craig Thompson appointed to Esperion Board as independent Class II director, effective July 1, 2025.
- Board expands from seven to eight members; Thompson will serve on Compliance, Nominating/Gov., and Commercial Committees.
- Thompson is CEO of Cerevance and has held leadership roles at Neurana, Anthera, Tetraphase, Trius, Pfizer, and Merck.
- He led commercial development of torcetrapib/atorvastatin at Pfizer and was involved in Trius' $700M+ acquisition by Cubist.
- Thompson holds a BComm from McMaster University and an MBA from the University of Notre Dame.

## SEC filing metadata
- accession: 0001628280-25-033612
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/0001628280-25-033612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025033612/espr-20250701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-033612
- JSON: https://secwatch.observer/filing/0001628280-25-033612.json
- Plain text: https://secwatch.observer/filing/0001628280-25-033612.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.